NCT00121732View on ClinicalTrials.gov

An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Solid Tumor Malignancies, Cancer
Interventions
DRUG

E7974

Maximum tolerated dose = 0.15 mg/m\^2 administered on Days 1, 8, 15 of 28-day cycle.

DRUG

E7974

Maximum tolerated dose = 0.37 mg/m\^2 administered on Days 1 and 8 of 21-day cycle.

Trial Locations (2)

46202

Indiana University, Indianapolis

78229

CTRC, San Antonio

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00121732 - An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies | Biotech Hunter | Biotech Hunter